Search | Clinical Trials Finder

Conditions: SARS-CoV-2
Interventions: Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose; Drug · Biological
Lead sponsor: Sean Liu; Other
Eligibility: 18 Years to 59 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Delirium
Interventions: Insulin, Saline; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Alcoholism, Alcohol Related Disorders
Interventions: oxytocin, placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rhinitis, Allergic, Perennial
Interventions: Ciclesonide nasal spray + placebo Azelastine, Ciclesonide nasal spray + Azelastine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 35
States / cities: Encinitas, California • Los Angeles, California • Mission Viejo, California + 32 more

Conditions: Prader-Willi Syndrome, Hyperphagia
Interventions: Intranasal Oxytocin (IN-OXT), Matched Placebo; Drug
Lead sponsor: Eric Hollander; Other
Eligibility: 5 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Saline, Insulin detemir, Insulin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 89 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Tacoma, Washington

Conditions: Influenza A Subtype H5N1 Infection
Interventions: Pandemic Influenza Vaccine, Placebo; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mucosal Immune Response to Influenza Vaccination
Interventions: FluMist (Live Attenuated Influenza Vaccine); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza, Healthy
Interventions: Trivalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Spinal Cord Injury
Interventions: Natesto testosterone intranasal gel, Ayr Saline Nasal Gel; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Influenza Vaccine
Interventions: Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo, IM Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 6
States / cities: Port Orange, Florida • Meridian, Idaho • Lenexa, Kansas + 3 more

Conditions: Pertussis, Pertussis Immunisation
Interventions: BPZE1, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Nonallergic Irritant Rhinitis
Interventions: Capsaicin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: Esketamine, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more

Conditions: Posttraumatic Stress Disorder
Interventions: Neuropeptide Y; Drug
Lead sponsor: James Murrough; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Allergic Rhinitis
Interventions: Fluticasone furoate, Placebo Fluticasone furoate, Oxymetazoline, Placebo Oxymetazoline; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depressive Disorder, Major
Interventions: Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 18
States / cities: Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more

Conditions: COVID-19 Prevention
Interventions: Q-Griffithsin, Placebo; Drug · Other
Lead sponsor: Kenneth Palmer; Other
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pain
Interventions: DEX-IN, Fentanyl, Placebo; Drug
Lead sponsor: Baudax Bio; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more

Conditions: Diabetic Gastroparesis
Interventions: Metoclopramide Nasal Spray, Placebo Nasal Spray; Drug
Lead sponsor: Evoke Pharma; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more

Conditions: Autism, Autism Spectrum Disorder
Interventions: 8 International Units (IU) of Oxytocin, 24IU of Oxytocin, 48IU of Oxytocin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pain, Post-operative
Interventions: Intranasal Dexmedetomidine, Intranasal Placebo; Drug · Other
Lead sponsor: Baudax Bio; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 3
States / cities: Bakersfield, California • Pasadena, California • San Antonio, Texas

Conditions: Autism, Autism Spectrum Disorder, ASD
Interventions: Vasopressin (USP) Injectable Solution [Vasostrict], Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

Post Operative Delirium Study

Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

How Healthy Adults Respond to the Nasal Flu Vaccine

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Testosterone and Neural Function

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

Evaluation of DEX-IN During Outpatient Procedures

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis

Autism Oxytocin Brain Project

Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy

Intranasal Vasopressin Treatment in Children With Autism